RxDoctor Payments Data

Brian Bonham, MD

Pediatrics · Smithsburg, MDNPI 1366407975

Payments from drug & device makers

$669in general payments, 2019–2025

Across 19 payments — averaging $35.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$280
  • AstraZeneca$136
  • GSK$58
  • Merck$51
  • Lilly USA, LLC$43
  • Johnson & Johnson$23
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669 in reported general payments places this provider in the 75th percentile of 1,307 pediatrics providers in Maryland.

See all pediatrics providers in Maryland

Medicare billing

Part B allowed, 2024
$222,901
Medicare patients
610
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$90,137
OzempicSemaglutide77$83,564
TrulicityDulaglutide44$72,022
XareltoRivaroxaban42$39,906
Tresiba Flextouch U-100Insulin Degludec42$34,902
JanuviaSitagliptin Phosphate27$31,157
Tresiba Flextouch U-200Insulin Degludec13$27,171
MounjaroTirzepatide26$25,397
FarxigaDapagliflozin Propanediol17$21,835
JardianceEmpagliflozin22$17,728
Breo ElliptaFluticasone/Vilanterol15$5,856
Rosuvastatin Calcium157$5,270
Atorvastatin Calcium295$4,754
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,004
Metoprolol Succinate159$3,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$43$97,41870 claims
Johnson & JohnsonXarelto$23$39,90642 claims
MerckJanuvia$51$31,15727 claims
AstraZenecaFarxiga$136$21,83517 claims
Boehringer IngelheimJardiance$15$17,72822 claims
GSKBreo Ellipta$58$5,85615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,307 pediatrics providers in Maryland.

Other pediatrics in Smithsburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →